Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
thrombocytopenia
Biotech
Nuvectis axes ovarian cancer program after seeing phase 1b data
Nuvectis Pharma dropped plans to develop NXP800 in ovarian cancer after tallying two unconfirmed partial responses in a phase 1b study.
Nick Paul Taylor
Jul 31, 2025 9:15am
Sanofi eyes broad portfolio for rilzabrutinib in immunology
Apr 23, 2021 10:00am
Sanofi snags speedy review for Principia BTK drug, Pompe program
Nov 18, 2020 10:34am
Argenx boosts pipeline with new version of lead drug
Jun 14, 2018 10:50am
Small cap Rigel drops on PhIII failure for lead fostamatinib
Oct 20, 2016 9:42am
